Alix Earle and Sister Ashtin Test Positive for BRCA2 Mutation After Mom's Cancer Diagnosis

Alix Earle is stepping into a far more personal spotlight. The social media titan and her sister, Ashtin Earle, have shared a critical health update after undergoing genetic testing. Both sisters tested positive for the BRCA2 gene mutation, a discovery that followed their mother's battle with cancer. The life-changing medical news unfolded while the family was shooting their Netflix series, *Earle Meets World*. While public chatter around the family frequently focuses on relationship updates and internet feud rumors, the show captured a much heavier reality playing out behind the scenes as cameras rolled. ## What happened on Earle Meets World with Alix Earle? During production of the streaming series, the Earle family permitted production crews to document their experience navigating medical testing and waiting for genetic panel results. The emotional footage highlights how their mother's cancer diagnosis prompted both Alix and Ashtin to get screened for inherited genetic markers. Carrying the BRCA2 gene mutation indicates an increased hereditary risk for developing breast and ovarian cancers. By learning their genetic status early, the sisters are positioned to work alongside their physicians to establish personalized monitoring routines and preventative healthcare strategies. ## Why did Alix Earle test for the BRCA2 gene? The decision to undergo genetic testing came directly in the wake of their mother confronting her own cancer diagnosis. Watching their parent endure the illness pushed both daughters to assess their personal health risks, ultimately leading to the shared positive test results documented on the show. The vulnerability displayed throughout *Earle Meets World* marks a major shift for Alix, who built her massive online fanbase primarily on beauty routines, lifestyle vlogs, and party recaps. By sharing such a complex health journey on a global platform, the family is bringing fresh visibility to genetic testing and hereditary risk awareness.